CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 89 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q2 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $482,000 | -22.6% | 4,070 | -22.8% | 0.00% | – |
| Q4 2020 | $623,000 | -96.9% | 5,269 | -97.0% | 0.00% | -100.0% |
| Q3 2020 | $19,824,000 | +20128.6% | 178,381 | +18442.7% | 0.01% | – |
| Q2 2020 | $98,000 | -90.9% | 962 | -90.4% | 0.00% | -100.0% |
| Q1 2020 | $1,081,000 | +17916.7% | 10,008 | +15063.6% | 0.00% | – |
| Q4 2019 | $6,000 | -25.0% | 66 | -21.4% | 0.00% | – |
| Q3 2019 | $8,000 | -80.0% | 84 | -80.3% | 0.00% | – |
| Q2 2019 | $40,000 | -67.2% | 427 | -68.4% | 0.00% | – |
| Q1 2019 | $122,000 | +3966.7% | 1,351 | +2602.0% | 0.00% | – |
| Q4 2018 | $3,000 | -62.5% | 50 | -50.0% | 0.00% | – |
| Q3 2018 | $8,000 | -99.9% | 100 | -99.9% | 0.00% | -100.0% |
| Q2 2018 | $13,308,000 | +630.8% | 133,983 | +495.5% | 0.00% | +300.0% |
| Q1 2018 | $1,821,000 | -61.4% | 22,500 | -62.4% | 0.00% | -66.7% |
| Q4 2017 | $4,716,000 | -63.4% | 59,873 | -57.2% | 0.00% | -66.7% |
| Q3 2017 | $12,895,000 | – | 139,767 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 164,500 | $15,011,000 | 10.32% |
| HHLR ADVISORS, LTD. | 2,751,200 | $251,047,000 | 6.99% |
| Dalton Investments, Inc. | 113,851 | $10,389,000 | 4.54% |
| Point72 Hong Kong Ltd | 115,939 | $10,579,000 | 4.17% |
| York Capital Management Global Advisors, LLC | 991,233 | $90,450,000 | 4.05% |
| RUDMAN ERROL M | 58,000 | $5,293,000 | 3.57% |
| Greenwoods Asset Management Ltd | 479,580 | $43,762,000 | 2.69% |
| Parametrica Management Ltd | 3,663 | $334,000 | 0.71% |
| Temasek Holdings (Private) Ltd | 990,000 | $90,338,000 | 0.62% |
| Athos Capital Ltd | 8,290 | $756,000 | 0.49% |